Background: Ectopic pregnancy is a major cause of maternal morbidity however, outcomes vary across populations. Objectives: This study aimed to evaluate the clinical outcomes and side effects of methotrexate in treating unruptured tubal ectopic pregnancy at a tertiary care hospital in Bangladesh. Methods success was defined as a ≥15% decline between these intervals and complete resolution without surgery. Data were analyzed using SPSS version 25.0. Results: The overall treatment success rate was 82%, with 72% of patients achieving resolution after a single dose and 10% requiring a second dose. Mean β-hCG resolution time was 31.6 ± 8.7 days. Significant predictors of success included baseline β-hCG levels <5000 mIU/mL (p = 0.02) and ectopic mass size <4.0 cm (p = 0.03). Adverse effects were mild, with abdominal pain (28%) and nausea/vomiting (22%) being the most common. Conclusion: Methotrexate is a highly effective, safe, and well-tolerated non-surgical option for appropriately selected patients with unruptured tubal ectopic pregnancy in tertiary care settings.
Rashed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: